Equity Overview
Price & Market Data
Price: $0.836
Daily Change: -$0.0₄1 / 0.01%
Daily Range: $0.836 - $0.849
Market Cap: $3,486,718
Daily Volume: 368
Performance Metrics
1 Week: -14.28%
1 Month: -26.62%
3 Months: -35.65%
6 Months: -80.77%
1 Year: -92.16%
YTD: -92.45%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.